Kiniksa Pharmaceuticals International (KNSA) Profit After Tax (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Profit After Tax for 10 years, with the latest figure at $22.6 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 164.57% year-over-year to $22.6 million; the trailing twelve-month figure through Mar 2026 stood at $73.1 million (up 531.02% YoY), and the FY2025 full-year result was $59.0 million, up 236.61% from the prior year.
• Profit After Tax for Q1 2026 stood at $22.6 million, up from $14.2 million in the prior quarter.
• The five-year high for Profit After Tax was $224.1 million in Q3 2022, with the low at -$25.2 million in Q1 2022.
• Historically, Profit After Tax has averaged $13.9 million across 5 years, with a median of $4.5 million in 2022.
• Annual changes were most pronounced in 2022 — Profit After Tax soared 833.67% — and 2024, when it slumped 135.22%.
• Kiniksa Pharmaceuticals International's Profit After Tax stood at $4.5 million in 2022, then soared by 465.73% to $25.2 million in 2023, then sank by 135.22% to -$8.9 million in 2024, then soared by 259.75% to $14.2 million in 2025, then surged by 59.11% to $22.6 million in 2026.
• The last three Profit After Tax figures came in at $22.6 million (Q1 2026), $14.2 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.